168 related articles for article (PubMed ID: 31257604)
21. [Ceftaroline: new possibilities of short-term courses of antibacterial therapy in hospitalized patients with extramural pneumonia].
Sinipal'nikov AI
Klin Med (Mosk); 2014; 92(1):21-7. PubMed ID: 25265655
[TBL] [Abstract][Full Text] [Related]
22. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
[TBL] [Abstract][Full Text] [Related]
23. Clinical cure with ceftriaxone versus ceftaroline or ceftobiprole in the treatment of staphylococcal pneumonia: a systematic review and meta-analysis.
Eljaaly K; Wali H; Basilim A; Alharbi A; Asfour HZ
Int J Antimicrob Agents; 2019 Aug; 54(2):149-153. PubMed ID: 31173864
[TBL] [Abstract][Full Text] [Related]
24. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.
Corrado ML
J Antimicrob Chemother; 2010 Nov; 65 Suppl 4():iv67-iv71. PubMed ID: 21115456
[TBL] [Abstract][Full Text] [Related]
25. Neutropenia in patients receiving long-term cefepime therapy for osteomyelitis.
Wong BB; Ko GJ
Am J Health Syst Pharm; 2003 Nov; 60(21):2229-32. PubMed ID: 14619113
[TBL] [Abstract][Full Text] [Related]
26. Use of ceftaroline after glycopeptide failure to eradicate meticillin-resistant Staphylococcus aureus bacteraemia with elevated vancomycin minimum inhibitory concentrations.
Paladino JA; Jacobs DM; Shields RK; Taylor J; Bader J; Adelman MH; Wilton GJ; Crane JK; Schentag JJ
Int J Antimicrob Agents; 2014 Dec; 44(6):557-63. PubMed ID: 25282169
[TBL] [Abstract][Full Text] [Related]
27. Ceftaroline for the treatment of methicillin-resistant
White BP; Barber KE; Stover KR
Am J Health Syst Pharm; 2017 Feb; 74(4):201-208. PubMed ID: 28179245
[TBL] [Abstract][Full Text] [Related]
28. Summary of ceftaroline fosamil clinical trial studies and clinical safety.
File TM; Wilcox MH; Stein GE
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S173-80. PubMed ID: 22903949
[TBL] [Abstract][Full Text] [Related]
29. DISC: Describing Infections of the Spine treated with Ceftaroline.
Watkins RR; Yendewa G; Burdette SD; Horattas S; Haller NA; Mangira C; Salata RA; Bonomo RA
J Glob Antimicrob Resist; 2018 Jun; 13():146-151. PubMed ID: 29337085
[TBL] [Abstract][Full Text] [Related]
30. Outpatient parenteral antimicrobial therapy in Enterococcus faecalis infective endocarditis.
Gil-Navarro MV; Lopez-Cortes LE; Luque-Marquez R; Galvez-Acebal J; de Alarcon-Gonzalez A
J Clin Pharm Ther; 2018 Apr; 43(2):220-223. PubMed ID: 29030859
[TBL] [Abstract][Full Text] [Related]
31. Biochemical and Haematological Predictors of Reduced Neutrophil Granulocyte Count associated with Intravenous Ceftriaxone Treatment.
Puri BK; Derham A; Monro JA
Rev Recent Clin Trials; 2018; 13(4):287-294. PubMed ID: 29769008
[TBL] [Abstract][Full Text] [Related]
32. Ceftaroline for the treatment of osteomyelitis caused by methicillin-resistant Staphylococcus aureus: a case series.
Lalikian K; Parsiani R; Won R; Chang E; Turner RB
J Chemother; 2018 Apr; 30(2):124-128. PubMed ID: 28697650
[TBL] [Abstract][Full Text] [Related]
33. Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin.
Varada NL; Sakoulas G; Lei LR; Chua J
Pharmacotherapy; 2015 Jun; 35(6):608-12. PubMed ID: 26037689
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Jandourek A; Smith A; Llorens L; Thye DA; Eckburg PB; Friedland HD
Hosp Pract (1995); 2014 Feb; 42(1):75-8. PubMed ID: 24566599
[TBL] [Abstract][Full Text] [Related]
35. High incidence of discontinuations due to adverse events in patients treated with ceftaroline.
Jain R; Chan JD; Rogers L; Dellit TH; Lynch JB; Pottinger PS
Pharmacotherapy; 2014 Jul; 34(7):758-63. PubMed ID: 24807197
[TBL] [Abstract][Full Text] [Related]
36. Ceftriaxone monotherapy in the treatment of low-risk febrile neutropenia.
Karthaus M; Wolf HH; Kämpfe D; Egerer G; Ritter J; Peters G; Südhoff T; Franke A; Heil G; Kullmann KH; Jürgens H
Chemotherapy; 1998; 44(5):343-54. PubMed ID: 9732151
[TBL] [Abstract][Full Text] [Related]
37. Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience.
Johnson LB; Ramani A; Guervil DJ
BMC Infect Dis; 2019 Feb; 19(1):183. PubMed ID: 30791894
[TBL] [Abstract][Full Text] [Related]
38. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
Poon H; Chang MH; Fung HB
Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785
[TBL] [Abstract][Full Text] [Related]
39. Review of ceftaroline fosamil microbiology: integrated FOCUS studies.
Critchley IA; Eckburg PB; Jandourek A; Biek D; Friedland HD; Thye DA
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii45-51. PubMed ID: 21482569
[TBL] [Abstract][Full Text] [Related]
40. The Importance of Perioperative Prophylaxis with Cefuroxime or Ceftriaxone in the Surgical Site Infections Prevention after Cranial and Spinal Neurosurgical Procedures.
Dimovska-Gavrilovska A; Chaparoski A; Gavrilovski A; Milenkovikj Z
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Sep; 38(2):85-97. PubMed ID: 28991759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
